Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 15/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 11/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307010 | 0.86 | ALDH1A1 (0.53) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL3456851 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL1307086 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL1309672 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL9989828 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL1308165 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL3455471 | 0.80 | LMNA (0.60) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL1307851 | 0.80 | ALDH1A1 (0.54) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL1307043 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MEN1HTTKMT2AAVPR1A | |
| SCHEMBL1307883 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MEN1HTTKMT2AAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | ALDH1A1 206/4885MEN1 2380/4885HTT 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.